Duchenne Muscular Dystrophy Treatment Market by Drug Type (Corticosteroids, Molecular-based Therapies)
Despite rapid advancements, the Duchenne Muscular Dystrophy Treatment Market faces multiple challenges. The rarity of the condition limits the number of patients eligible for clinical trials, making research costly and time-consuming. Additionally, most treatments only slow disease progression, not cure it.
High drug prices create accessibility barriers, especially in developing nations. The complexity of genetic therapies also raises concerns about long-term safety and potential side effects. Regulatory hurdles, though improving, still slow down the approval process in some regions.
Addressing these challenges will require international cooperation, government incentives, and new funding models to ensure treatments reach all who need them.
1 View
